Early Kilogram Scale Delivery of MK-7845 as a Potential COVID-19 Therapy: Rapid Process Development of Key Intermediates-Reference-Cited by-同舟云学术

Early Kilogram Scale Delivery of MK-7845 as a Potential COVID-19 Therapy: Rapid Process Development of Key Intermediates

Published:2024-05-16 Issue:6 Volume:28 Page:2150-2156
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Peng Feng¹^ORCID,Qi Ji¹^ORCID,Zhang Jin²,Wang Enkai²,Cao Xiaohui³,Chen Lu³,Fan Chao²,Fan Wei³,Feng Cheng³,Lin Mingxiang¹,Liu Mingjie²,Nawrat Christopher C.¹^ORCID,Schultz Danielle M.¹^ORCID,Song Chaohui²,Wang Feng³,Yin Jingjun¹,Zhang Yuming²

Affiliation:

1. Department of Process Research and Development, MRL, Merck & Co., Inc., Rahway, New Jersey 07065 United States

2. Department of Synthetic Chemistry, Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, China

3. Shanghai Syn The All Pharmaceutical Co. Ltd., Shanghai 201507, China

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.4c00003

Reference42 articles.

1. WHO. Covid-19 Dashboard. https://data.who.int/dashboards/covid19/cases

2. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

3. An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19

4. bOwen, D. R.; Pettersson, M. Y.; Reese, M. R.; Sammons, M. F.; Tuttle, J. B.; Verhoest, P. R.; Wei, L.; Yang, Q.; Yang, X. Preparation of peptidomimetic nitriles as SARS-CoV-2 3CL protease inhibitors and methods for the treatment of COVID-19. WO2021250648, 2021.

5. Development of the Commercial Manufacturing Process for Nirmatrelvir in 17 Months

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rapid End-Game Process Development and First GMP Production of MK-7845: An Experimental Antiviral Treatment for COVID-19;Organic Process Research & Development;2024-06-06